Description

Erlonat Tablets contain Erlotinib, a prescription targeted anticancer medicine belonging to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) class. Erlotinib works by blocking EGFR signaling, which can slow or stop the growth of certain cancer cells that rely on this pathway. It is used only in specific clinical settings and under the supervision of an experienced oncologist. Erlonat Tablets are taken orally as prescribed. The dose and duration of treatment are determined by the patient's diagnosis, molecular testing results (where applicable), overall health, and response to therapy. Key Benefits Contains Erlotinib, an EGFR tyrosine kinase inhibitor. Oral tablet formulation for convenient daily administration. Used as part of targeted treatment strategies for selected cancers. Helps inhibit the growth and spread of EGFR-dependent cancer cells. Manufactured according to high pharmaceutical quality standards. Indications Erlonat Tablets may be prescribed for the treatment of: Non-Small Cell Lung Cancer (NSCLC) with appropriate EGFR mutations, as determined by molecular testing. Pancreatic cancer, in combination with gemcitabine, in selected patients according to approved treatment guidelines. Treatment decisions should be made by a qualified oncology specialist based on the patient's clinical condition and current medical guidelines. Administration Take orally once daily, exactly as prescribed by your healthcare provider. Take the tablet on an empty stomach (at least 1 hour before or 2 hours after a meal). Swallow the tablet whole with water; do not crush or chew. Continue treatment unless instructed otherwise by your physician. Regular monitoring of treatment response and side effects is recommended.